Key advances include CNS-targeted hesperidin delivery for leptin sensitization in obesity-associated sleep-disordered breathing, and ROS-responsive nanotherapeutics attenuating intermittent hypoxia-induced cognitive impairment through NRF2/KEAP1/HO-1 pathway modulation (198, 199). The gene discussed is LEP; the disease is obesity disorder.